The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Antibody Drug Conjugates Contract Manufacturing Market Research Report 2025
Synopsis
ADCs are mainly composed of three parts: antibodies, linkers, and cytotoxic loads. They are a type of bioactive cytotoxic drugs that are linked to monoclonal antibodies through chemical bonds and use monoclonal antibodies as carriers to target and transport cytotoxic drugs to target cells. Complex that works. The design concept of ADC was first proposed by Paul Ehrlich in the early 20th century. In 2000, the U.S. Food and Drug Administration (FDA) approved the first ADC drug, Mylotarg® (gemtuzumab ozogamicin), for the treatment of acute myeloid myelopathy in adults. Leukemic cell lines, marking the beginning of the era of ADC-targeted cancer therapy.
The global Antibody Drug Conjugates Contract Manufacturing market was valued at US$ 2827.3 million in 2023 and is anticipated to reach US$ 9332.5 million by 2030, witnessing a CAGR of 18.9% during the forecast period 2024-2030.
Key global companies of Antibody Drug Conjugates Contract Manufacturing (ADC) include Lonza, Merck, Recipharm, Thermo Fisher, AbbVie, Piramal Pharma Solutions, Catalent, Sterling Pharma Solutions and Curia. The top three players are Lonza, Merck and Recipharm, which together account for about 50% of the global market share. The largest player is Lonza Group. From the production side, the global players are mainly concentrated in North America and Europe. North America accounts for about 35% of the global market share. In terms of type, IgG1 dominates the global antibody drug conjugate contract manufacturing market. In terms of application, solid tumor applications account for more than half of the market.
This report aims to provide a comprehensive presentation of the global market for Antibody Drug Conjugates Contract Manufacturing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody Drug Conjugates Contract Manufacturing.
Report Scope
The Antibody Drug Conjugates Contract Manufacturing market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antibody Drug Conjugates Contract Manufacturing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody Drug Conjugates Contract Manufacturing companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Lonza Group
Merck KGaA
Recipharm
Thermo Fisher Scientific
Abbvie
Piramal Pharma Solutions
Catalent
Sterling Pharma Solutions
Curia
Novasep
Ajinomoto Bio-Pharma Services
BSP Pharmaceuticals
Cerbios-Pharma
Goodwin Biotechnology
Segment by Type
IgG1
IgG4
Segment by Application
Solid Tumors
Hematological Malignancies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antibody Drug Conjugates Contract Manufacturing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
ADCs are mainly composed of three parts: antibodies, linkers, and cytotoxic loads. They are a type of bioactive cytotoxic drugs that are linked to monoclonal antibodies through chemical bonds and use monoclonal antibodies as carriers to target and transport cytotoxic drugs to target cells. Complex that works. The design concept of ADC was first proposed by Paul Ehrlich in the early 20th century. In 2000, the U.S. Food and Drug Administration (FDA) approved the first ADC drug, Mylotarg® (gemtuzumab ozogamicin), for the treatment of acute myeloid myelopathy in adults. Leukemic cell lines, marking the beginning of the era of ADC-targeted cancer therapy.
The global Antibody Drug Conjugates Contract Manufacturing market was valued at US$ 2827.3 million in 2023 and is anticipated to reach US$ 9332.5 million by 2030, witnessing a CAGR of 18.9% during the forecast period 2024-2030.
Key global companies of Antibody Drug Conjugates Contract Manufacturing (ADC) include Lonza, Merck, Recipharm, Thermo Fisher, AbbVie, Piramal Pharma Solutions, Catalent, Sterling Pharma Solutions and Curia. The top three players are Lonza, Merck and Recipharm, which together account for about 50% of the global market share. The largest player is Lonza Group. From the production side, the global players are mainly concentrated in North America and Europe. North America accounts for about 35% of the global market share. In terms of type, IgG1 dominates the global antibody drug conjugate contract manufacturing market. In terms of application, solid tumor applications account for more than half of the market.
This report aims to provide a comprehensive presentation of the global market for Antibody Drug Conjugates Contract Manufacturing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody Drug Conjugates Contract Manufacturing.
Report Scope
The Antibody Drug Conjugates Contract Manufacturing market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antibody Drug Conjugates Contract Manufacturing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody Drug Conjugates Contract Manufacturing companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Lonza Group
Merck KGaA
Recipharm
Thermo Fisher Scientific
Abbvie
Piramal Pharma Solutions
Catalent
Sterling Pharma Solutions
Curia
Novasep
Ajinomoto Bio-Pharma Services
BSP Pharmaceuticals
Cerbios-Pharma
Goodwin Biotechnology
Segment by Type
IgG1
IgG4
Segment by Application
Solid Tumors
Hematological Malignancies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antibody Drug Conjugates Contract Manufacturing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antibody Drug Conjugates Contract Manufacturing Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 IgG1
1.2.3 IgG4
1.3 Market by Application
1.3.1 Global Antibody Drug Conjugates Contract Manufacturing Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Solid Tumors
1.3.3 Hematological Malignancies
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antibody Drug Conjugates Contract Manufacturing Market Perspective (2019-2030)
2.2 Antibody Drug Conjugates Contract Manufacturing Growth Trends by Region
2.2.1 Global Antibody Drug Conjugates Contract Manufacturing Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Antibody Drug Conjugates Contract Manufacturing Historic Market Size by Region (2019-2024)
2.2.3 Antibody Drug Conjugates Contract Manufacturing Forecasted Market Size by Region (2025-2030)
2.3 Antibody Drug Conjugates Contract Manufacturing Market Dynamics
2.3.1 Antibody Drug Conjugates Contract Manufacturing Industry Trends
2.3.2 Antibody Drug Conjugates Contract Manufacturing Market Drivers
2.3.3 Antibody Drug Conjugates Contract Manufacturing Market Challenges
2.3.4 Antibody Drug Conjugates Contract Manufacturing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antibody Drug Conjugates Contract Manufacturing Players by Revenue
3.1.1 Global Top Antibody Drug Conjugates Contract Manufacturing Players by Revenue (2019-2024)
3.1.2 Global Antibody Drug Conjugates Contract Manufacturing Revenue Market Share by Players (2019-2024)
3.2 Global Antibody Drug Conjugates Contract Manufacturing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Antibody Drug Conjugates Contract Manufacturing Revenue
3.4 Global Antibody Drug Conjugates Contract Manufacturing Market Concentration Ratio
3.4.1 Global Antibody Drug Conjugates Contract Manufacturing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antibody Drug Conjugates Contract Manufacturing Revenue in 2023
3.5 Antibody Drug Conjugates Contract Manufacturing Key Players Head office and Area Served
3.6 Key Players Antibody Drug Conjugates Contract Manufacturing Product Solution and Service
3.7 Date of Enter into Antibody Drug Conjugates Contract Manufacturing Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Antibody Drug Conjugates Contract Manufacturing Breakdown Data by Type
4.1 Global Antibody Drug Conjugates Contract Manufacturing Historic Market Size by Type (2019-2024)
4.2 Global Antibody Drug Conjugates Contract Manufacturing Forecasted Market Size by Type (2025-2030)
5 Antibody Drug Conjugates Contract Manufacturing Breakdown Data by Application
5.1 Global Antibody Drug Conjugates Contract Manufacturing Historic Market Size by Application (2019-2024)
5.2 Global Antibody Drug Conjugates Contract Manufacturing Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Antibody Drug Conjugates Contract Manufacturing Market Size (2019-2030)
6.2 North America Antibody Drug Conjugates Contract Manufacturing Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Antibody Drug Conjugates Contract Manufacturing Market Size by Country (2019-2024)
6.4 North America Antibody Drug Conjugates Contract Manufacturing Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antibody Drug Conjugates Contract Manufacturing Market Size (2019-2030)
7.2 Europe Antibody Drug Conjugates Contract Manufacturing Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Antibody Drug Conjugates Contract Manufacturing Market Size by Country (2019-2024)
7.4 Europe Antibody Drug Conjugates Contract Manufacturing Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Market Size (2019-2030)
8.2 Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Market Size by Region (2019-2024)
8.4 Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Antibody Drug Conjugates Contract Manufacturing Market Size (2019-2030)
9.2 Latin America Antibody Drug Conjugates Contract Manufacturing Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Antibody Drug Conjugates Contract Manufacturing Market Size by Country (2019-2024)
9.4 Latin America Antibody Drug Conjugates Contract Manufacturing Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antibody Drug Conjugates Contract Manufacturing Market Size (2019-2030)
10.2 Middle East & Africa Antibody Drug Conjugates Contract Manufacturing Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Antibody Drug Conjugates Contract Manufacturing Market Size by Country (2019-2024)
10.4 Middle East & Africa Antibody Drug Conjugates Contract Manufacturing Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lonza Group
11.1.1 Lonza Group Company Detail
11.1.2 Lonza Group Business Overview
11.1.3 Lonza Group Antibody Drug Conjugates Contract Manufacturing Introduction
11.1.4 Lonza Group Revenue in Antibody Drug Conjugates Contract Manufacturing Business (2019-2024)
11.1.5 Lonza Group Recent Development
11.2 Merck KGaA
11.2.1 Merck KGaA Company Detail
11.2.2 Merck KGaA Business Overview
11.2.3 Merck KGaA Antibody Drug Conjugates Contract Manufacturing Introduction
11.2.4 Merck KGaA Revenue in Antibody Drug Conjugates Contract Manufacturing Business (2019-2024)
11.2.5 Merck KGaA Recent Development
11.3 Recipharm
11.3.1 Recipharm Company Detail
11.3.2 Recipharm Business Overview
11.3.3 Recipharm Antibody Drug Conjugates Contract Manufacturing Introduction
11.3.4 Recipharm Revenue in Antibody Drug Conjugates Contract Manufacturing Business (2019-2024)
11.3.5 Recipharm Recent Development
11.4 Thermo Fisher Scientific
11.4.1 Thermo Fisher Scientific Company Detail
11.4.2 Thermo Fisher Scientific Business Overview
11.4.3 Thermo Fisher Scientific Antibody Drug Conjugates Contract Manufacturing Introduction
11.4.4 Thermo Fisher Scientific Revenue in Antibody Drug Conjugates Contract Manufacturing Business (2019-2024)
11.4.5 Thermo Fisher Scientific Recent Development
11.5 Abbvie
11.5.1 Abbvie Company Detail
11.5.2 Abbvie Business Overview
11.5.3 Abbvie Antibody Drug Conjugates Contract Manufacturing Introduction
11.5.4 Abbvie Revenue in Antibody Drug Conjugates Contract Manufacturing Business (2019-2024)
11.5.5 Abbvie Recent Development
11.6 Piramal Pharma Solutions
11.6.1 Piramal Pharma Solutions Company Detail
11.6.2 Piramal Pharma Solutions Business Overview
11.6.3 Piramal Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Introduction
11.6.4 Piramal Pharma Solutions Revenue in Antibody Drug Conjugates Contract Manufacturing Business (2019-2024)
11.6.5 Piramal Pharma Solutions Recent Development
11.7 Catalent
11.7.1 Catalent Company Detail
11.7.2 Catalent Business Overview
11.7.3 Catalent Antibody Drug Conjugates Contract Manufacturing Introduction
11.7.4 Catalent Revenue in Antibody Drug Conjugates Contract Manufacturing Business (2019-2024)
11.7.5 Catalent Recent Development
11.8 Sterling Pharma Solutions
11.8.1 Sterling Pharma Solutions Company Detail
11.8.2 Sterling Pharma Solutions Business Overview
11.8.3 Sterling Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Introduction
11.8.4 Sterling Pharma Solutions Revenue in Antibody Drug Conjugates Contract Manufacturing Business (2019-2024)
11.8.5 Sterling Pharma Solutions Recent Development
11.9 Curia
11.9.1 Curia Company Detail
11.9.2 Curia Business Overview
11.9.3 Curia Antibody Drug Conjugates Contract Manufacturing Introduction
11.9.4 Curia Revenue in Antibody Drug Conjugates Contract Manufacturing Business (2019-2024)
11.9.5 Curia Recent Development
11.10 Novasep
11.10.1 Novasep Company Detail
11.10.2 Novasep Business Overview
11.10.3 Novasep Antibody Drug Conjugates Contract Manufacturing Introduction
11.10.4 Novasep Revenue in Antibody Drug Conjugates Contract Manufacturing Business (2019-2024)
11.10.5 Novasep Recent Development
11.11 Ajinomoto Bio-Pharma Services
11.11.1 Ajinomoto Bio-Pharma Services Company Detail
11.11.2 Ajinomoto Bio-Pharma Services Business Overview
11.11.3 Ajinomoto Bio-Pharma Services Antibody Drug Conjugates Contract Manufacturing Introduction
11.11.4 Ajinomoto Bio-Pharma Services Revenue in Antibody Drug Conjugates Contract Manufacturing Business (2019-2024)
11.11.5 Ajinomoto Bio-Pharma Services Recent Development
11.12 BSP Pharmaceuticals
11.12.1 BSP Pharmaceuticals Company Detail
11.12.2 BSP Pharmaceuticals Business Overview
11.12.3 BSP Pharmaceuticals Antibody Drug Conjugates Contract Manufacturing Introduction
11.12.4 BSP Pharmaceuticals Revenue in Antibody Drug Conjugates Contract Manufacturing Business (2019-2024)
11.12.5 BSP Pharmaceuticals Recent Development
11.13 Cerbios-Pharma
11.13.1 Cerbios-Pharma Company Detail
11.13.2 Cerbios-Pharma Business Overview
11.13.3 Cerbios-Pharma Antibody Drug Conjugates Contract Manufacturing Introduction
11.13.4 Cerbios-Pharma Revenue in Antibody Drug Conjugates Contract Manufacturing Business (2019-2024)
11.13.5 Cerbios-Pharma Recent Development
11.14 Goodwin Biotechnology
11.14.1 Goodwin Biotechnology Company Detail
11.14.2 Goodwin Biotechnology Business Overview
11.14.3 Goodwin Biotechnology Antibody Drug Conjugates Contract Manufacturing Introduction
11.14.4 Goodwin Biotechnology Revenue in Antibody Drug Conjugates Contract Manufacturing Business (2019-2024)
11.14.5 Goodwin Biotechnology Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
